Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 11/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 3/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24921789 | 0.83 | NPC1 (0.38) | NOTUMNPC1RAB9AALDH1A1MAPT | |
| SCHEMBL25986827 | 0.74 | NOTUM (0.39) | NOTUMTP53NPC1RAB9AKDM4E | |
| SCHEMBL25693366 | 0.74 | NOTUM (0.46) | NOTUMKDM4EALDH1A1MAPTLMNA | |
| SCHEMBL24920787 | 0.74 | ALDH1A1 (0.43) | NOTUMNPC1RAB9AKDM4EALDH1A1 | |
| SCHEMBL24922191 | 0.71 | RAB9A (0.50) | NOTUMTP53NPC1RAB9AMAPT | |
| SCHEMBL24922122 | 0.71 | RAB9A (0.40) | NOTUMNPC1RAB9AALDH1A1MAPT | |
| SCHEMBL23370157 | 0.71 | CYP1A2 (0.39) | KDM4EALDH1A1 | |
| SCHEMBL28394924 | 0.70 | NOTUM (0.50) | NOTUMKDM4ERXFP1 | |
| SCHEMBL21547876 | 0.70 | ACACB (0.40) | NOTUMTP53NPC1RAB9AKDM4E | |
| SCHEMBL25986790 | 0.69 | TSHR (0.37) | NOTUMTP53NPC1RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230257352-A1 | RAF KINASE INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC | 2023-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257352-A1 | RAF KINASE INHIBITORS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | NOTUM 3620/4885TP53 62/4885NPC1 2922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.